Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
about
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the LiteratureBotulinum toxin A for the Treatment of Overactive BladderHow botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?The role of botulinum toxin A in treating neurogenic bladderBotulinum toxin injections for treating neurogenic detrusor overactivityEvaluation and Management of Neurogenic Bladder: What Is New in China?Autonomic Dysregulation in Multiple SclerosisOnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic reviewUse of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art reviewSecondary and tertiary treatments for multiple sclerosis patients with urinary symptomsNeurogenic bladder in spinal cord injury patientsBotulinum toxin-what urologic uses does the data support?Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.Emerging treatments for overactive bladder: clinical potential of botulinum toxins.What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and Neurogenic ModuleThe role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO).Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.Botulinum toxin-A for the treatment of overactive bladder: UK contributions.The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA.Changes in chemical coding of sympathetic chain ganglia (SChG) neurons supplying porcine urinary bladder after botulinum toxin (BTX) treatment.Application of purified botulinum type a neurotoxin to treat experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasiaEfficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPreserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's diseaseUse of onabotulinumtoxinA for overactive bladder with concomitant warfarin.Management of lower urinary tract dysfunction in patients with neurological disordersBotulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladderDoes Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivityReduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiologyFourteen-day administration of corticosterone may induce detrusor overactivity symptoms.Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.A urological challenge: Voiding dysfunction in multiple sclerosis.Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity.Ensuring patient adherence to clean intermittent self-catheterization.
P2860
Q26749613-3E832E44-B99A-4184-A44B-73C2F5EE94AFQ26764765-0DAB65E4-0B6B-4D8E-B42C-BF3B06BC07E0Q26765052-8F29E34B-D4F3-4EB4-902F-C017CC86DD94Q26767310-40935649-6D29-4EB0-89AD-D5842D08D05FQ26775670-CCAE216A-A751-42BB-93B4-4AE5AB46CF53Q26798495-A0207EFC-8C40-4C74-8DDA-7857D1807578Q26799341-28932C80-AFFE-4228-855B-BE607F1D1977Q26826756-A6D24408-EA3F-4D51-9B73-0D23DE4FE9E1Q26851170-38A05402-621A-4887-947B-56EB111EF85DQ28070040-B69EFDFD-BF95-455E-AB90-79FAB1936A5EQ28087196-3045410D-A877-4A7B-B991-3D08EA4AFF54Q30620372-00409A72-9974-4B11-885D-DC81C88CD3F5Q30837390-27D9F307-E507-4CDA-A6F0-8409C31252FBQ30984304-816E3A84-FB61-4A1A-8044-EE971D8BFF38Q33689757-4C0E7BD6-E35B-4772-A0C8-7D1E7643AD4FQ33819934-5FA0BD20-33BA-4C7C-89D5-55F1041D39A2Q34334025-5F31EEB1-48DE-4969-BECB-37E95116C252Q35044823-3C645FC0-29F2-4607-874A-F97A7C46AD17Q35237161-AF4FADAB-4436-46E8-8EF5-F9A2BD1A8285Q35741907-9A8D55E0-34C1-46F8-9A38-7C3A79C158CEQ35898622-B9FCB513-3016-4FBD-8B6E-745F6D542B3FQ35980887-C53A33D9-8BA4-4EE2-B07B-646701B71B4DQ36056160-CB97CF0B-46DD-40E3-9943-2DC0C2D83D1CQ36087246-6B69D2BA-0A17-4B53-983C-52D4299D3BA7Q36123446-6EB0A368-5387-41A5-8345-5BCEA532EB81Q36160965-EB9878D6-1128-46BE-BEB6-E5A8A7BDCB13Q36284726-46603071-6CE9-4D59-A83C-39AC7854A015Q36329632-85994817-2F6E-424D-ACC7-5206A3A7B3C6Q36401506-AEB8443F-471A-4E42-8749-F1F78771DE02Q36804908-03442926-31F1-44F6-8CE7-D003848DB64EQ37248174-E944D7AC-E3BD-4055-8F43-941586B727C1Q37281359-389ECDAA-1A75-4C56-8C31-62E77349F32DQ37299990-3D04570F-7F38-400A-9AA2-E0776CFE128BQ37342324-D9CBFED0-3F6E-4930-8A64-72ECA1AAE9F7Q37390990-C9FA2B67-2EC8-430A-B072-9271AE28320AQ37496473-A45494A9-C869-41DE-B760-8BFB01107C02Q37536741-BBA1218C-B2D6-40B9-9DC9-2E6F28851007Q37572770-4A181851-B986-483B-8E14-14AA75A20E60Q37581341-7EF22883-6C4D-4DE1-B900-79A7F9363ECCQ37591817-6C54C6E2-69AD-4447-B143-CA48BA4EBA12
P2860
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@en
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@nl
type
label
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@en
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@nl
prefLabel
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@en
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@nl
P2093
P1433
P1476
Efficacy and safety of onabotu ...... ind, placebo-controlled trial.
@en
P2093
Catherine Thompson
Cornelia Haag-Molkenteller
Grace Daniell
Mitchell Brin
Philip Aliotta
Sender Herschorn
P304
P356
10.1016/J.EURURO.2011.07.002
P407
P577
2011-07-13T00:00:00Z